The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 601–700 of 1,002
The current use and attitudes towards tumor genome sequencing in breast cancer
Gingras, I., Sonnenblick, A., de Azambuja, E., Paesmans, M., Delaloge, S., Aftimos, P. G., Piccart, M. J., Sotiriou, C. P., Ignatiadis, M., & Azim, H. A. (2016) · Scientific Reports · doi:10.1038/srep22517 · Cited by 32
Off-label use of targeted therapies in oncology
Levêque, D. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i2.253 · Cited by 32
de la Fouchardière, C., Cohen, R., Malka, D., Guimbaud, R., Bourien, H., Lièvre, A., Cacheux, W., Artru, P., François, É., Gilabert, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0914 · Cited by 32
Diagnosis and treatment of cystic lung disease
Park, S., & Lee, E. J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.242 · Cited by 31
Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Yates, L. R., & Desmedt, C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2548 · Cited by 33
Kanojia, D., Garg, M., Martinez, J., Anand, M. T., Luty, S. B., Doan, N., SAID, J. W., Forscher, C. A., Tyner, J. W., & Koeffler, H. P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0540-x · Cited by 30
RetractedSignorovitch, J., Zhou, Z., Ryan, J., Anhorn, R., & Chawla, A. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1549056 · Cited by 31
BRAF Mutation and Its Importance in Colorectal Cancer
Luu, L., & Price, T. J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82571 · Cited by 31
Fujikawa, K., Teramukai, S., Yokota, I., & Daimon, T. (2019) · Biometrical Journal · doi:10.1002/bimj.201800404 · Cited by 31
Kato, S., Okamura, R., Adashek, J. J., Khalid, N. K., Lee, S., Nguyen, V. T., Sicklick, J. K., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.142547 · Cited by 33
Scheiter, A., Hierl, F., Lüke, F., Keil, F., Heudobler, D., Einhell, S., Klier-Richter, M., Konstandin, N. P., Weber, F., Scheiter, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02120-x · Cited by 32
Automated eligibility screening and monitoring for genotype-driven precision oncology trials
Eubank, M. H., Hyman, D. M., Kanakamedala, A., Gardos, S. M., Wills, J., & Stetson, P. D. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw020 · Cited by 30
Self-citationBRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis
Maxwell, R., Garzón-Muvdi, T., Lipson, E. J., Sharfman, W. H., Bettegowda, C., Redmond, K. J., Kleinberg, L. R., Ye, X., & Lim, M. K. (2016) · International Journal of Cancer · doi:10.1002/ijc.30241 · Cited by 31
Mirmomen, S. M., Sirajuddin, A., Nikpanah, M., Symons, R., Paschall, A. K., Papageorgiou, I., Gahl, W. A., O’Brien, K., Estrada‐Veras, J. I., & Malayeri, A. A. (2018) · European Radiology · doi:10.1007/s00330-018-5421-3 · Cited by 31
Turashvili, G., Grisham, R. N., Chiang, S., DeLair, D. F., Park, K. J., Soslow, R. A., & Murali, R. (2018) · Histopathology · doi:10.1111/his.13651 · Cited by 31
Complexity of Delivering Precision Medicine: Opportunities and Challenges
Davis, A. A., McKee, A. E., Kibbe, W. A., & Villaflor, V. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200279 · Cited by 33
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular AgePreprint
Chakraborty, R., Abdel-Wahab, O. I., & Durham, B. H. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034892 · Cited by 31
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
Prete, A., Matrone, A., Gambale, C., Torregrossa, L., Minaldi, E., Romei, C., Ciampi, R., Molinaro, E., & Elisei, R. (2021) · Cancers · doi:10.3390/cancers13133200 · Cited by 30
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Li, H., Zhang, Y., Xu, Y., Huang, Z., Cheng, G., Xie, M., Zhou, Z., Yu, Y., Xi, W., & Fan, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05510-4 · Cited by 33
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Xu, M. M., Pu, Y., Zhang, Y., & Fu, Y. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.007 · Cited by 31
Ivanov, M. V., Лактионов, К. К., Breder, V. V., Chernenko, P., Новикова, Е. И., Телышева, Е. Н., Musienko, S. V., Baranova, A. V., & Mileyko, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1125-8 · Cited by 30
Zaun, G., Schüler, M., Herrmann, K., & Tannapfel, A. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0157 · Cited by 30
Kurzrock, R., Colevas, A. D., Olszanski, A. J., Akerley, W., Arteaga, C. L., Carson, W. E., Clark, J. W., DiPersio, J. F., Ettinger, D. S., Morgan, R. J., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0163 · Cited by 30
The possibility of clinical sequencing in the management of cancer
Kou, T., Kanai, M., Matsumoto, S., Okuno, Y., & Muto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw018 · Cited by 30
The Future of Cardiovascular Therapeutics
MacRae, C. A., Roden, D. M., & Loscalzo, J. (2016) · Circulation · doi:10.1161/circulationaha.116.023555 · Cited by 29
Major milestones in translational oncology
Dragani, T. A., Castells, A., Kulasingam, V., Diamandis, E. P., Earl, H. M., Iams, W. T., Lovly, C. M., Sedelaar, J. P. M., & Schalken, J. A. (2016) · BMC Medicine · doi:10.1186/s12916-016-0654-y · Cited by 31
Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation
Caliò, A., Eble, J. N., Hes, O., Martignoni, G., Harari, S. E., Williamson, S. R., Brunelli, M., Osunkoya, A. O., Wang, L., Compérat, É., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11117 · Cited by 29
Heydt, C., Kostenko, A. V., Merkelbach‐Bruse, S., Wolf, J. M., & Büttner, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw303 · Cited by 28
Self-citationde Langen, A. J., & Smit, E. F. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016670555 · Cited by 31
A paradigm shift in biomarker guided oncology drug development
Jørgensen, J. T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.36 · Cited by 29
Su, X., Li, P., Han, B., Hao, J., Liang, Q., Wang, H., Gu, M., Cai, J., Li, S., Zhou, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01831-y · Cited by 29
Shi, Z., Zhao, Q., Lv, B., Qu, X., Han, X., Wang, H., Qiu, J., & Hua, K. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.399 · Cited by 29
Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31
Self-citationXie, J., Liu, J., Zhao, M., Li, X., Wang, Y., Zhao, Y., Cao, H., Ji, M., Chen, M., & Hou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043418 · Cited by 29
Blay, J., Casali, P. G., Ray-Coquard, I. L., Seckl, M. J., Gietema, J. A., de Herder, W. W., Caplin, M. E., Klümpen, H., Gléhen, O., Wyrwicz, L. S., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100861 · Cited by 29
Self-citationThe Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas
Peh, J., Fan, T. M., Wycislo, K. L., Roth, H. S., & Hergenrother, P. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0025 · Cited by 29
Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma
Mochizuki, H., & Breen, M. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12275 · Cited by 28
Wojtaś, B., Gielniewski, B., Wojnicki, K., Maleszewska, M., Mondal, S. S., Nauman, P., Grajkowska, W., Glaß, R., Schüller, U., Herold‐Mende, C. C., et al. (2019) · Cancers · doi:10.3390/cancers11030284 · Cited by 28
Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study
Okada, T., Saotome, T., Nagao, T., Masubuchi, T., Fushimi, C., Matsuki, T., Takahashi, H., Miura, K., Tsukahara, K., & Tada, Y. (2019) · In Vivo · doi:10.21873/invivo.11549 · Cited by 28
Montés, A. F., Grávalos, C., Pericay, C., Safont, M. J., Benavides, M., Élez, E., Alfonso, P. G., García-Paredes, B., Carrato, A., & Aranda, E. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.003 · Cited by 28
Capatina, C. A.-M., Hinojosa‐Amaya, J. M., Poiană, C., & Fleseriu, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1802243 · Cited by 30
Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 30
Shi, H., He, H., Cui, L., Kvedaraite, E., Bian, Z., Huang, T., Lee, C., Li, Z., He, J., Gong, Y., et al. (2021) · Blood · doi:10.1182/blood.2020009064 · Cited by 28
BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?
Bouchè, V., Aldegheri, G., Donofrio, C. A., Fioravanti, A., Roberts-Thomson, S. J., Fox, S. B., Schettini, F., & Generali, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772052 · Cited by 29
Kenny, K., Broom, A. F., Page, A., Prainsack, B., Wakefield, C. E., Itchins, M., Lwin, Z., & Khasraw, M. (2021) · Sociology of Health & Illness · doi:10.1111/1467-9566.13389 · Cited by 28
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions
Riudavets, M., Cascetta, P., & Planchard, D. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.014 · Cited by 30
Targeting the Tumor-Tumor Microenvironment Crosstalk
Badve, S., & Gökmen‐Polar, Y. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230362 · Cited by 28
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
Ros, J., Rodríguez-Castells, M., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236794 · Cited by 29
Self-citationTransforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application
Kim, E. S., Atlas, J., Ison, G., & Ersek, J. L. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_155880 · Cited by 28
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 29
Laird, J. H., Ma, J., Chau, K., Chelius, M. R., Shi, W., Zhang, Z., Lok, B. H., & Yahalom, J. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.10.053 · Cited by 28
Pan, J., Zhou, H. K., Zhu, S.-B., Huang, J.-L., Zhao, X.-X., Ding, H., & Pan, Y.-L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s170105 · Cited by 28
CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
Iyer, P. C., Cote, G. J., Hai, T., Gule-Monroe, M. K., Bui, J. H., Williams, M. D., Hess, K. R., Hofmann, M.-C. C., Dadu, R., Zafereo, M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00173 · Cited by 28
Self-citationSustained Response to Vemurafenib in a BRAF V600E -Mutated Anaplastic Thyroid Carcinoma Patient
Prager, G. W., Koperek, O., Mayerhoefer, M. E., Müllauer, L., Wrba, F., Niederle, B., Zielinski, C. C., & Raderer, M. (2016) · Thyroid · doi:10.1089/thy.2015.0575 · Cited by 27
Origins based clinical and molecular complexities of epithelial ovarian cancer
Muinao, T., Pal, M., & Boruah, H. P. D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.06.036 · Cited by 29
Molecular genetics and therapeutic targets of pediatric low-grade gliomas
Tateishi, K., Nakamura, T., & Yamamoto, T. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00340-3 · Cited by 27
Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics
Roy, R., Winteringham, L. N., Lassmann, T., & Forrest, A. R. R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0273 · Cited by 28
Genova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 27
Innovative trial design in precision oncology
Tsimberidou, A. M., Müller, P., & Ji, Y. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.006 · Cited by 29
Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective
Kanakis, M. G., Petrou, P., Lourida, P., & Georgalas, I. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.05.013 · Cited by 27
Comparison of sampling methods for next generation sequencing for patients with lung cancer
Kunimasa, K., Matsumoto, S., Nishino, K., Honma, K., Maeda, N., Kuhara, H., Tamiya, M., Inoue, T., Kawamura, T., Kimura, T., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4632 · Cited by 29
Li, Y., & Izem, R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5496 · Cited by 28
Current and promising treatment strategies in glioma
Śledzińska, P., Bebyn, M. G., Furtak, J., Koper, A., & Koper, K. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0060 · Cited by 28
Hondo, N., Kitazawa, M., Koyama, M., Nakamura, S., Tokumaru, S., Miyazaki, S., Kataoka, M., Seharada, K., & Soejima, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216264 · Cited by 28
Trametinib-Induced Remission of an MEK1-Mutated Langerhans Cell Histiocytosis
Papapanagiotou, M., Griewank, K., Hillen, U., Schimming, T. T., Moeller, L. C., Führer, D., Zimmer, L., Roesch, A., Sucker, A., Schadendorf, D., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00070 · Cited by 27
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
Kato, S., Subbiah, V., & Kurzrock, R. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0127 · Cited by 27
Self-citationIsolated hypothalamic-pituitary langerhans’ cell histiocytosis in female adult
Tan, H., Yu, K., Yu, Y., An, Z., & Li, J. (2019) · Medicine · doi:10.1097/md.0000000000013853 · Cited by 27
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 28
New Targets in Non–Small Cell Lung Cancer
Park, S. J., More, S., Murtuza, A., Woodward, B. D., & Husain, H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.010 · Cited by 26
Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition
Johnson, D. B., & Dahlman, K. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1795 · Cited by 26
Cheng, Y., Zhang, J., Qin, S., & Hua, H. Q. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s176914 · Cited by 26
Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials
Liu, J., Mao, J. J. J., Wang, X. S., & Lin, H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000404 · Cited by 26
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 29
Kondo, T. (2020) · Cancer Science · doi:10.1111/cas.14669 · Cited by 28
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Boilève, A., Hilmi, M., Delaye, M., Tijeras‐Raballand, A., & Neuzillet, C. (2021) · Cancers · doi:10.3390/cancers13112708 · Cited by 27
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Attalla, K., DiNatale, R. G., Rappold, P. M., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4058 · Cited by 27
Weissman, R., Diamond, E. L., Haroche, J., Durham, B. H., Aubart, F. C., Buthorn, J. J., Amoura, Z., Emile, J., Mazor, R. D., Shomron, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01472-2 · Cited by 26
Self-citationNew designs for basket clinical trials in oncology
Simon, R. M. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1372779 · Cited by 26
Precision oncology in liver cancer
Sullivan, K. M., Kenerson, H. L., Pillarisetty, V. G., Riehle, K. J., & Yeung, R. S. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.14 · Cited by 26
Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF -mutant ganglioglioma
Touat, M., Gratieux, J., Auliac, S., Sejean, K., Aldéa, S., Savatovsky, J., Perkins, G., Blons, H., Ligon, K. L., Idbaïh, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006171 · Cited by 26
Self-citationA pooled analysis of published, basket trials in cancer medicine
Hazim, A. Z., & Prasad, V. K. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.035 · Cited by 26
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
Dişel, U., Madison, R. W., Abhishek, K., Chung, J., Trabucco, S. E., Matos, A. O., Frampton, G. M., Albacker, L. A., Reddy, V. P., Karadurmuş, N., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0528 · Cited by 27
Busch, E., Kreutzfeldt, S., Agaimy, A., Mechtersheimer, G., Horak, P., Brors, B., Hutter, B., Fröhlich, M., Uhrig, S., Mayer, P., et al. (2020) · Molecular Case Studies · doi:10.1101/mcs.a005553 · Cited by 26
Troussard, X., Maître, E., & Paillassa, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27240 · Cited by 25
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
Subbiah, V., Othus, M. K. D., Palma, J., Cuglievan, B., & Kurzrock, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-100051 · Cited by 28
Self-citationCouraud, S., Barlési, F., Fontaine-Deraluelle, C., Debieuvre, D., Merlio, J., Moreau, L., Beau‐Faller, M., Veillon, R., Mosser, J., Freijat, F. A., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.016 · Cited by 26
National Cancer Institute Basket/Umbrella Clinical Trials
Chen, A. P., Eljanne, M., Harris, L. N., Malik, S. M., & Seibel, N. L. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000389 · Cited by 25
Córdova‐Delgado, M., Pinto, M. P., Retamal, I. N., Muñoz‐Medel, M., Bravo, M. L., Fernández, M. F., Cisternas, B., Mondaca, S., Sanchez, C. G., Galindo, H., et al. (2019) · Cancers · doi:10.3390/cancers11091275 · Cited by 25
Salem, J., Bretagne, M., Lebrun‐Vignes, B., Waintraub, X., Gandjbakhch, E., Hidden‐Lucet, F., Gougis, P., Bachelot, A., & Funck‐Brentano, C. (2019) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.06.008 · Cited by 26
Zhang, Y., Wu, X., Yan, K., Lee, C.-H., Cheng, F., Li, Y., Zhuang, Y., Ghaemmaghami, J., Chuang, K., Liu, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129344 · Cited by 24
Smith-Cohn, M., Davidson, C. J., Colman, H., & Cohen, A. L. (2019) · CNS Oncology · doi:10.2217/cns-2019-0018 · Cited by 25
Palmieri, L., Lavolé, J., Dermine, S., Brézault, C., Dhooge, M., Barré, A., Chaussade, S., & Coriat, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107517 · Cited by 25
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology
Rohrberg, K. S., & Lassen, U. (2021) · Drugs · doi:10.1007/s40265-020-01459-w · Cited by 25
Grayling, M. J., Bigirumurame, T., Cherlin, S., Ouma, L. O., Zheng, H., & Wason, J. M. S. (2021) · BMC Rheumatology · doi:10.1186/s41927-021-00192-5 · Cited by 25
Jiang, L., Nie, L., Yan, F., & Yuan, Y. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106460 · Cited by 25
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
Chen, H., Ke, T., Huang, C., Jiang, J.-K., Chen, C., Hsieh, Y., Teng, H., Lin, B., Liang, Y., Su, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764912 · Cited by 24
Emerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 26
Mutation based approaches to the treatment of anaplastic thyroid cancer
McCrary, H. C., Aoki, J., Huang, Y., Chadwick, B. E., Kerrigan, K., Witt, B. L., Hunt, J. P., & Abraham, D. (2022) · Clinical Endocrinology · doi:10.1111/cen.14679 · Cited by 25
The Role of the Kinase Inhibitors in Thyroid Cancers
Cuomo, F., Giani, C., & Cobellis, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051040 · Cited by 25
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
